Okuyucu, Esra E.Guven, OguzDuman, TaskinGorur, SadikMelek, Ismet M.Akcin, SonerYilmazer, Serkan2024-09-182024-09-1820090161-64121743-1328https://doi.org/10.1179/174313209X382548https://hdl.handle.net/20.500.12483/12482Objective: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. Method: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). Results: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. Conclusion: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors. [Neurol Res 2009; 31: 313-315]eninfo:eu-repo/semantics/closedAccessTadalafilphosphodiesterase type 5 inhibitorelectroencephalographyArticle31331331510.1179/174313209X382548190361802-s2.0-65749096748Q3WOS:000265960300017Q3